Cholestyramine - A useful adjunct for the treatment of patients with fecal incontinence

Jose M. Remes-Troche, Ramazan Ozturk, Carrie Philips, Mary Stessman, Satish Sanku Chander Rao

Research output: Contribution to journalArticle

30 Citations (Scopus)

Abstract

Aim/Background: Cholestyramine may improve fecal incontinence, but its use has not been assessed. We report our experience with the use of cholestyramine in the treatment of fecal incontinence. Materials and methods: Twenty-one patients (19 female, mean age 65 years) with fecal incontinence (≥1 episode/week) received cholestyramine along with biofeedback therapy (group A). Stool frequency, stool consistency (Bristol scale), number of incontinent episodes, satisfaction with bowel function (VAS), and anorectal physiology were assessed at 3 months and at 1 year after treatment. Data were compared with a matched group of 21 incontinent subjects (19 female, mean age 64 years) who received biofeedback alone (group B). Results: At 3 months and at 1 year, group A patients showed decreased stool frequency (p<0.01), stool consistency (p=0.001), and number of incontinent episodes (p<0.04). In contrast, stool frequency (p=0.8) and stool consistency (0.23) were not different from baseline in group B subjects. In both groups, there was improvement in the satisfaction with bowel function (p<0.05), anal sphincter pressures (p<0.05) and ability to retain saline infusion (p<0.05). Mean dose of cholestyramine used was 3.6 g; 13 subjects (62%) required dose titration, and 7 (33%) subjects reported minor side effects. Conclusion: Cholestyramine is safe and useful adjunct for the treatment of diarrhea and fecal incontinence. Most patients require small doses, and dose titration is important. The improvement in stool characteristics favors a drug effect, over and above the benefits of biofeedback therapy.

Original languageEnglish (US)
Pages (from-to)189-194
Number of pages6
JournalInternational Journal of Colorectal Disease
Volume23
Issue number2
DOIs
StatePublished - Feb 1 2008
Externally publishedYes

Fingerprint

Cholestyramine Resin
Fecal Incontinence
Therapeutics
Aptitude
Anal Canal
Group Psychotherapy
Diarrhea
Research Design
Pressure
Pharmaceutical Preparations
Biofeedback (Psychology)

Keywords

  • Cholestyramine
  • Diarrhea
  • Fecal incontinence
  • Medical treatment

ASJC Scopus subject areas

  • Gastroenterology

Cite this

Cholestyramine - A useful adjunct for the treatment of patients with fecal incontinence. / Remes-Troche, Jose M.; Ozturk, Ramazan; Philips, Carrie; Stessman, Mary; Rao, Satish Sanku Chander.

In: International Journal of Colorectal Disease, Vol. 23, No. 2, 01.02.2008, p. 189-194.

Research output: Contribution to journalArticle

Remes-Troche, Jose M. ; Ozturk, Ramazan ; Philips, Carrie ; Stessman, Mary ; Rao, Satish Sanku Chander. / Cholestyramine - A useful adjunct for the treatment of patients with fecal incontinence. In: International Journal of Colorectal Disease. 2008 ; Vol. 23, No. 2. pp. 189-194.
@article{d95b8389fcf04f1896252de97611603f,
title = "Cholestyramine - A useful adjunct for the treatment of patients with fecal incontinence",
abstract = "Aim/Background: Cholestyramine may improve fecal incontinence, but its use has not been assessed. We report our experience with the use of cholestyramine in the treatment of fecal incontinence. Materials and methods: Twenty-one patients (19 female, mean age 65 years) with fecal incontinence (≥1 episode/week) received cholestyramine along with biofeedback therapy (group A). Stool frequency, stool consistency (Bristol scale), number of incontinent episodes, satisfaction with bowel function (VAS), and anorectal physiology were assessed at 3 months and at 1 year after treatment. Data were compared with a matched group of 21 incontinent subjects (19 female, mean age 64 years) who received biofeedback alone (group B). Results: At 3 months and at 1 year, group A patients showed decreased stool frequency (p<0.01), stool consistency (p=0.001), and number of incontinent episodes (p<0.04). In contrast, stool frequency (p=0.8) and stool consistency (0.23) were not different from baseline in group B subjects. In both groups, there was improvement in the satisfaction with bowel function (p<0.05), anal sphincter pressures (p<0.05) and ability to retain saline infusion (p<0.05). Mean dose of cholestyramine used was 3.6 g; 13 subjects (62{\%}) required dose titration, and 7 (33{\%}) subjects reported minor side effects. Conclusion: Cholestyramine is safe and useful adjunct for the treatment of diarrhea and fecal incontinence. Most patients require small doses, and dose titration is important. The improvement in stool characteristics favors a drug effect, over and above the benefits of biofeedback therapy.",
keywords = "Cholestyramine, Diarrhea, Fecal incontinence, Medical treatment",
author = "Remes-Troche, {Jose M.} and Ramazan Ozturk and Carrie Philips and Mary Stessman and Rao, {Satish Sanku Chander}",
year = "2008",
month = "2",
day = "1",
doi = "10.1007/s00384-007-0391-y",
language = "English (US)",
volume = "23",
pages = "189--194",
journal = "International Journal of Colorectal Disease",
issn = "0179-1958",
publisher = "Springer Verlag",
number = "2",

}

TY - JOUR

T1 - Cholestyramine - A useful adjunct for the treatment of patients with fecal incontinence

AU - Remes-Troche, Jose M.

AU - Ozturk, Ramazan

AU - Philips, Carrie

AU - Stessman, Mary

AU - Rao, Satish Sanku Chander

PY - 2008/2/1

Y1 - 2008/2/1

N2 - Aim/Background: Cholestyramine may improve fecal incontinence, but its use has not been assessed. We report our experience with the use of cholestyramine in the treatment of fecal incontinence. Materials and methods: Twenty-one patients (19 female, mean age 65 years) with fecal incontinence (≥1 episode/week) received cholestyramine along with biofeedback therapy (group A). Stool frequency, stool consistency (Bristol scale), number of incontinent episodes, satisfaction with bowel function (VAS), and anorectal physiology were assessed at 3 months and at 1 year after treatment. Data were compared with a matched group of 21 incontinent subjects (19 female, mean age 64 years) who received biofeedback alone (group B). Results: At 3 months and at 1 year, group A patients showed decreased stool frequency (p<0.01), stool consistency (p=0.001), and number of incontinent episodes (p<0.04). In contrast, stool frequency (p=0.8) and stool consistency (0.23) were not different from baseline in group B subjects. In both groups, there was improvement in the satisfaction with bowel function (p<0.05), anal sphincter pressures (p<0.05) and ability to retain saline infusion (p<0.05). Mean dose of cholestyramine used was 3.6 g; 13 subjects (62%) required dose titration, and 7 (33%) subjects reported minor side effects. Conclusion: Cholestyramine is safe and useful adjunct for the treatment of diarrhea and fecal incontinence. Most patients require small doses, and dose titration is important. The improvement in stool characteristics favors a drug effect, over and above the benefits of biofeedback therapy.

AB - Aim/Background: Cholestyramine may improve fecal incontinence, but its use has not been assessed. We report our experience with the use of cholestyramine in the treatment of fecal incontinence. Materials and methods: Twenty-one patients (19 female, mean age 65 years) with fecal incontinence (≥1 episode/week) received cholestyramine along with biofeedback therapy (group A). Stool frequency, stool consistency (Bristol scale), number of incontinent episodes, satisfaction with bowel function (VAS), and anorectal physiology were assessed at 3 months and at 1 year after treatment. Data were compared with a matched group of 21 incontinent subjects (19 female, mean age 64 years) who received biofeedback alone (group B). Results: At 3 months and at 1 year, group A patients showed decreased stool frequency (p<0.01), stool consistency (p=0.001), and number of incontinent episodes (p<0.04). In contrast, stool frequency (p=0.8) and stool consistency (0.23) were not different from baseline in group B subjects. In both groups, there was improvement in the satisfaction with bowel function (p<0.05), anal sphincter pressures (p<0.05) and ability to retain saline infusion (p<0.05). Mean dose of cholestyramine used was 3.6 g; 13 subjects (62%) required dose titration, and 7 (33%) subjects reported minor side effects. Conclusion: Cholestyramine is safe and useful adjunct for the treatment of diarrhea and fecal incontinence. Most patients require small doses, and dose titration is important. The improvement in stool characteristics favors a drug effect, over and above the benefits of biofeedback therapy.

KW - Cholestyramine

KW - Diarrhea

KW - Fecal incontinence

KW - Medical treatment

UR - http://www.scopus.com/inward/record.url?scp=37349055139&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=37349055139&partnerID=8YFLogxK

U2 - 10.1007/s00384-007-0391-y

DO - 10.1007/s00384-007-0391-y

M3 - Article

VL - 23

SP - 189

EP - 194

JO - International Journal of Colorectal Disease

JF - International Journal of Colorectal Disease

SN - 0179-1958

IS - 2

ER -